3 days popular7 days popular1 month popular3 months popular

First-in-class antibody mixture shows clinical activity against Tx-resistant, advanced CRC

Patients with advanced colorectal tumors without mutations in the RAS genes derive substantial benefit from anti-EGFR therapies; however, the disease eventually progresses, leaving these patients with few alternative therapeutic options. Over the last decade, some of the mechanisms driving resistance have been identified, but despite intensive research, treatment options available for patients have not improved, [...]